Trial Profile
A Study of the Pharmacokinetics of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma and Impaired Renal Function
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Mar 2023
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Melphalan flufenamide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacokinetics
- Acronyms BRIDGE
- Sponsors Oncopeptides
- 04 Feb 2022 This trial has been discontinued in Greece (Date of the global end of the trial : 22-Dec-2021), according to European Clinical Trials Database record.
- 02 Feb 2022 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped: The sponsor decided to terminate the study following an FDA request of a partial clinical hold.
- 02 Feb 2022 This trial has been discontinued in Poland (End Date: 22 Dec 2021), according to European Clinical Trials Database record.